retatrutide approval status eli lilly Lilly's triple agonist delivers up to 71.2 lbs of weight loss Eli Lilly's Retatrutide Clears Two

Certificates of Analysis should accompany the shipment

Currently, higher doses of subcutaneous semaglutide (once weekly at 7.2mg) are being evaluated in phase III clinical trials

Leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years

GLP-1 Medications Semaglutide, tirzepatide & expert dosing Weight Loss Surgery Sleeve gastrectomy & gastric bypass options Dr

Common side effects include: Nausea, especially during the first few weeks at a new dose Mild diarrhea or constipation as digestion adjusts Decreased appetite, which is typically desired but can feel intense early on Occasional headaches or mild fatigue Injection site reactions like redness or light swelling Most of these effects are temporary and tend to ease as your body adjusts

Tirzepatide is a dual agonist (GLP-1 + GIP) that is FDA-approved as Mounjaro and Zepbound and commercially available by prescription